New stroke drug could boost recovery when given hours after symptoms

NCT ID NCT07389460

Not yet recruiting Disease control Sponsor: First Affiliated Hospital Xi'an Jiaotong University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests whether giving a clot-busting drug called rhPro-UK before a mechanical clot removal procedure improves recovery for people with severe stroke. About 820 participants who had a stroke 4.5 to 24 hours earlier will receive either the drug or a placebo, followed by the standard clot removal. The main goal is to see if more people can live independently 90 days later.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: recombinant human prourokinase (rhPro-UK)
What this could lead to: If it works, this could offer a new treatment to improve recovery for stroke patients who can't get clot-busting drugs right away.
What could go wrong: This is still being tested, so it may not work better than placebo. There is also a risk of bleeding in the brain, which could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cerebral artery occlusion ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE ISCHEMIC STROKE

Contacts and locations

Locations

First Affiliated Hospital of Xi'an Jiaotong University

Xi'an, Shaanxi, China
Henan Provincial People's Hospital

Zhengzhou, Henan, China
Loudi Central Hospital

Loudi, Hunan, China
Qinghai Provincial People's Hospital

Xining, Qinghai, China
Shanxi Cardiovascular Hospital

Taiyuan, Shanxi, China
The First Affiliated Hospital of Shihezi University

Shihezi, Xinjiang Uygur Autonomous Region, China
The First Hospital of Lanzhou University

Lanzhou, Gansu, China
The Second Hospital of Dalian Medical University

Dalian, Liaoning, China
The Third Hospital of Hebei Medical University

Shijiazhuang, Hebei, China
Xuanwu Hospital Capital Medical University

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.